Sharon Fekrat, MD, FACS, FASRS contributed to the recent Ophthalmology Times article, “8 things to know about aflibercept 8 mg for retinal vascular disease.” The article is based on insights from the 8‑part podcast discussion she moderated, “Optimizing Retinal Care with Next‑Generation Anti‑VEGF Agents: Insights from Clinical Practice.”
The piece highlights the growing clinical impact of aflibercept 8 mg (EYLEA HD), which offers faster drying, longer durability, and the potential for fewer injections while maintaining treatment goals for conditions such as AMD, DME, and RVO. The FDA recently expanded its approval of the 8 mg dose to include macular edema following retinal vein occlusion, with flexible dosing options that may reduce burden for both patients and clinics.
Through her role as moderator, Dr. Fekrat helped guide a discussion on how next‑generation anti‑VEGF therapies are shaping individualized care and improving outcomes for patients with retinal vascular disease.